HanAll Biopharma Invests in Interon to Seek Collaboration Op..
Woburn, MA – December 11, 2023
HanAll Biopharma’s partner NurrOn Pharmaceuticals
Inc., a clinical-stage biopharmaceutical company dedicated to developing novel,
targeted therapeutics for the treatment of Parkinson's disease (PD) and other
Nurr1-related human disorders, is pleased to announce the appointment of Dr.
Almira Chabi, MD, EGMP to its Board of Directors, effective November 24, 2023.
Dr. Chabi who is currently Chief Medical Officer and
Chief Development Officer at HanAll Pharmaceutical International brings a
wealth of experience and expertise to NurrOn’s board with a successful track
record as a physician-scientist with deep experiences as an executive as well
as board member. Dr. Chabi has led programs across multiple therapeutic areas
including neurology, immunology, oncology, and ophthalmology as well as
applications of artificial intelligence. She is also serving on the Scientific and
Medical Research Funding Grants Working Group at the California Institute for
Regenerative Medicine.
Dr. Chabi previously held the position of Vice
President and Global Therapeutic Area Head for Glaucoma & Neuroprotection
as well as Lead for Artificial Intelligence Programs at Santen. Prior to
Santen, she worked at Genentech including a senior role on a pivotal Phase III
program encompassing over 20 countries. Dr. Chabi began her pharmaceutical
career at Merck in the Neuroscience & Ophthalmology Clinical Research
Group, working on a range of projects within Ophthalmology as well as
Neuroscience leading to multiple successful NDA filings.
In addition to expertise in drug discovery and
development, as well as biomarker and device development, she has been
extensively involved in due diligences for business development and venture
capital teams. Dr. Chabi is also an alumna of Wharton Business School’s
Executive Management Program and has served as a board representative for
multiple companies.
"We are delighted to welcome Dr. Almira Chabi, to
our Board of Directors. She possesses a unique blend of skills and insights
that will undoubtedly contribute to the strategic direction and success of
NurrOn Pharmaceuticals," said Deog Joong Kim, Ph.D, CEO of NurrOn Pharmaceuticals.
Dr. Chabi expressed enthusiasm about joining NurrOn
and shared, "I am honored to be a part of NurrOn’s Board of Directors.
NurrOn is a company that has consistently demonstrated a deep commitment to
discovering and developing innovative treatments that have the potential to
improve clinical outcomes for Parkinson’s patients. I look forward to working
collaboratively with the board and the executive team to contribute to the
continued growth and success of the organization."
Dr. Chabi joins an esteemed group of professionals on
the NurrOn Board, and her appointment aligns with the company's strategic goals
for the future.
About NurrOn Pharmaceuticals
NurrOn Pharmaceuticals
is a clinical-stage biopharmaceutical company dedicated to developing novel,
targeted therapeutics for the treatment of Parkinson's disease (PD) and other
Nurr1-related incurable human disorders. Through targeting Nurr1, the master
regulator for dopaminergic neuron development and maintenance, we aim to
develop a paradigm changing PD treatment to improve patients' quality of life.
While currently there are only symptomatic treatment options for patients with
PD, there have not been any successful therapies to slow or prevent the
progression of the disease. We believe that disease-modifying therapies will be
achieved through targeting Nurr1, which has generated supportive data as a new
druggable PD target. NurrOn was awarded a substantial grant from Michael J. Fox
Foundation in support of the Phase 1 clinical trial of ATH-399A/HL192, that
initiated in the second half of 2023. For further information on NurrOn
Pharmaceuticals, please visit our official website or contact info@nurronpharma.com.
About
HanAll Biopharma
HanAll
Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with presence
in Korea, the USA, Japan, and Indonesia with a mission of making meaningful
contributions to patients' lives by introducing innovative, impactful medicines
to address severe unmet medical needs. HanAll has been operating a portfolio of
pharmaceutical products for 50 years.
HanAll
has also expanded its focus in recent years to immunology, oncology, neurology,
and ophthalmology to discover and develop innovative medicines for patients
with diseases for which there are no effective treatments. Its lead pipeline
asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in
Phase 3 and Phase 2 trials across the world for the treatment of autoimmune
diseases including generalized myasthenia gravis (gMG), thyroid eye disease
(TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’
disease (GD). Another main asset, HL036 (INN: tanfanercept), a TNF-alpha
inhibitor protein, is under development in Phase 3 clinical studies in the US
for the treatment of dry eye disease. For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact
HanAll PR/IR (pr@hanall.com, ir@hanall.com).